Waltham, MA-based BG Medicine has again adjusted its plans for an initial public offering, this time aiming to raise about $33.3 million, roughly half of what it was shooting for last year. The diagnostics company revealed in a regulatory filing today that it is aiming to price a 4.75-million-share initial public offering at $7 per share, after withdrawing its IPO proposal in December, which was looking to price the 4.75 million shares at between $13 and $15 each. BG Medicine’s road to going public has been rocky; the company also withdrew its IPO plans in 2008.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
